P797: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF COMBINATION POZELIMAB AND CEMDISIRAN THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO SWITCH FROM ECULIZUMAB

• Richard Kelly,
• Nicola Houghton,
• Talha Munir,
• Petra Muus,
• Nora Youngs,
• Lisa Aurand,
• Brian Senk,
• Rodrigo Pavani,
• Lorah Perlee,
• Amal Souttou,
• Morag Griffin

Affiliations

Richard Kelly

1 St James’s University Hospital, Leeds, United Kingdom

Nicola Houghton

1 St James’s University Hospital, Leeds, United Kingdom

Talha Munir

1 St James’s University Hospital, Leeds, United Kingdom

Petra Muus

1 St James’s University Hospital, Leeds, United Kingdom

Nora Youngs

1 St James’s University Hospital, Leeds, United Kingdom

Lisa Aurand

2 Regeneron Pharmaceuticals, Inc., Tarrytown, United States

Brian Senk

2 Regeneron Pharmaceuticals, Inc., Tarrytown, United States

Rodrigo Pavani

2 Regeneron Pharmaceuticals, Inc., Tarrytown, United States

Lorah Perlee

2 Regeneron Pharmaceuticals, Inc., Tarrytown, United States

Amal Souttou

2 Regeneron Pharmaceuticals, Inc., Tarrytown, United States

Morag Griffin

1 St James’s University Hospital, Leeds, United Kingdom